1.12
-0.04 (-3.45%)
-0.04 (-3.45%)
Upgrade to Real-Time
Afterhours
| Volume | 482,765 |
|
|||||
| News | - | ||||||
| Day High | 1.18 | Low High |
|||||
| Day Low | 1.11 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Outlook Therapeutics Inc | OTLK | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.04 | -3.45% | 1.12 | 17:20:49 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.16 | 1.11 | 1.18 | 1.17 | 1.16 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 2,108 | 482,765 | $ 1.15 | $ 553,999 | - | 0.6839 - 2.12 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 18:44:34 | 10 | $ 1.19 | USD |
Period:
Draw Mode:
Outlook Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 287.47M | 256.67M | 180.71M | $ - | $ - | -0.31 | -3.70 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 14.90M | 4.30% |
Outlook Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical OTLK Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.09 | 1.20 | 1.08 | 1.15 | 335,400 | 0.03 | 2.75% |
| 1 Month | 1.04 | 1.37 | 1.01 | 1.18 | 577,260 | 0.08 | 7.69% |
| 3 Months | 1.07 | 1.37 | 0.80 | 1.08 | 482,570 | 0.05 | 4.67% |
| 6 Months | 1.12 | 1.37 | 0.80 | 1.14 | 481,363 | 0.00 | 0.0% |
| 1 Year | 1.40 | 2.12 | 0.6839 | 1.41 | 801,636 | -0.28 | -20.0% |
| 3 Years | 0.96 | 4.26 | 0.499 | 1.72 | 1,641,387 | 0.16 | 16.67% |
| 5 Years | 5.60 | 20.00 | 0.4011 | 1.88 | 1,608,814 | -4.48 | -80.0% |
Outlook Therapeutics Description
| Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. |